University of Toronto
3359 Mississauga Road N.
224 articles about University of Toronto
New AI Tool Makes Speedy Gene-Editing Possible
The researchers at NYU Grossman School of Medicine and the University of Toronto who designed the tool say it promises to accelerate the development of gene therapies on a large scale.
The partnership framework agreement allows Moderna and U of T to collaborate across a broad variety of areas, ranging from molecular genetics to biomedical engineering, biochemistry and more.
Recent technological advancements have pushed pharma employees to embrace new technologies and innovations in different areas.
At this time, 73% of Americans are immune to Omicron, and it could rise to 80% by mid-March. For that and more COVID-19 news, continue reading.
AbbVie and the University of Toronto Establish Endowed Chair in Ethnodermatology
AbbVie has made a CDN $3-million donation to establish a pioneering AbbVie Chair in Ethnodermatology at the University of Toronto's Temerty Faculty of Medicine.
Creative Destruction Lab Joins University of Washington’s Foster School of Business, Establishing CDL-Seattle
Focus on Computational Health Merges Strengths in Artificial Intelligence and Machine Learning with Biological and Biomedical Expertise to Launch Companies That Revolutionize Diagnostic and Therapeutic Outcomes
Sansero Life Sciences Announces Joint Study With the University of Toronto to Advance Clinical Research of Psychedelic Medications
Sansero Life Sciences , a leader in the development of psilocybin-based medicines, announced today that it has partnered with the University of Toronto to complete a preclinical study on the effects of low-dose psilocybin. The study will bring new scientific understanding to psilocybin metabolism in the mammalian body and
Researchers at the University of Toronto have identified a protein called Importin-11 that transports beta-catenin into the nucleus of colon cancer cells, where it drives cell proliferation.
Absolute Antibody Partners with the Recombinant Antibody Network to Facilitate Access to Engineered Recombinant Antibodies
200+ recombinant antibodies to be engineered into new formats to advance research
FACIT and University of Toronto launch precision medicine company: Cellular Analytics
Next generation liquid biopsy platform to revolutionize companion diagnostics
A team of researchers from the University of Toronto has combined CRISPR-based gene-editing technology with small biomagnetic devices to sort large populations of mixed cell types.
University of Toronto and Amgen Foundation Welcome Canadian Students to Prestigious Amgen Scholars Program
For the first time, Amgen Foundation grant offers Canadian undergraduate students the opportunity to gain hands-on research experience with world-leading U of T researchers
Mothers Know Best: How Egg Cells Choose Their Best Powerhouses to Pass On
Developing egg cells conduct tests to select the healthiest of their energy-making machines to be passed to the next generation.
St. Baldrick's Foundation Awards One-of-a-Kind Grant to Aid in Childhood Cancer Research Discovery
St. Baldrick's Robert J. Arceci Innovation Award provides scientists opportunity to pursue unrestricted research
University of Toronto Partners with IMS for Emergency Radiology Simulation
IMS Web Viewer™ Selected for ER Simulator Exam Study
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Research Roundup: Gene Therapy for Deafness, Autism Genes, Breakthroughs in Parkinson’s and ALS, ...
3/1/2019There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Boehringer Ingelheim and Eli Lilly released data from their Empagliflozin as Adjunctive to inSulin thErapy (EASE) Phase III trial in type 1 diabetes.
CCAB And Triumvira Immunologics Announce Triumvira’s License Agreement with University of Toronto for the Discovery of Antibody Drug Development Candidates
The agreement provides Triumvira with an exclusive license for antibodies discovered at the U of T on specified therapeutic targets.
Medicine by Design and Creative Destruction Lab partner to accelerate the commercialization of world-class research in regenerative medicine
A new partnership between Medicine by Design and the Creative Destruction Lab (CDL) will strengthen Toronto's biomedical ecosystem by bringing together the University of Toronto's (U of T) world-class research in regenerative medicine and the CDL's proven seed-stage program for science-based companies.